• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Gabonectin Presentation 8 3 09   Power Point File
 

Gabonectin Presentation 8 3 09 Power Point File

on

  • 1,113 views

 

Statistics

Views

Total Views
1,113
Views on SlideShare
1,107
Embed Views
6

Actions

Likes
0
Downloads
0
Comments
0

3 Embeds 6

http://www.slideshare.net 3
http://www.lifegen.org 2
http://lifegen.org 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Gabonectin Presentation 8 3 09   Power Point File Gabonectin Presentation 8 3 09 Power Point File Presentation Transcript

    • Presented By: LifeGen ® , Inc. ‘ Gene-Guided Precision Nutrition’ 09/23/09 Confidential Information
    • NOTICE The following information has not been evaluated by the Food and Drug Administration, and is not intended to diagnose, treat, cure or prevent any disease. While LifeGen believes this information is true and accurate, all information is provided “as is, with faults” and the Parties makes no representations or warranties with respect to the compliance of this information with governmental regulations. 09/23/09 Confidential Information
    • Obesity and Addiction 09/23/09 Confidential Information
    • Conceptual Framework
      • Demystifying Traditional Weight Loss Tactics
      • Defining and understanding optimal Health and Wellness
      • Unlocking neurogenetics of reward linked to optimal health
      • Paradigm Shift Utilizing A multi-pathway “Genetic Positioning Map (GPS)”- Nutrigenomic Principles
      • Neurophysiological and genetic actions of Gabonectin are easily explained and applied to achieving optimal Health
      • Commercialization Issues
      • Patented Genomic Solution – Novel Exclusive Protected Optimal Health Nutraceutical
      09/23/09 Confidential Information
      • Obesity is due to:
      • An imbalance between energy intake and expenditure, i.e. too much in and not enough out
      • A Lack of Willpower and self-control
      • A loss of self-respect
      • An increase in self-loathing
      • A Psychological Disorder
      Demystifying Traditional Weight Loss Tactics Old Traditional View 09/23/09 Confidential Information
    • Obesity Etiology: The Real Causes
      • Consumption of nutrient deficient calorie rich foods
        • Deprivation syndrome (nutrient-based)
        • Thrifty-gene concept (energy stored in times of plenty)
        • Inadequate activity (to keep healthy & burn more calories)
      • Stressful life experiences
      • Environmental toxins
      • Gene-Environmental Expression - Epigenetics
        • The above conditions promote protective genetic ‘survival insurance’ and pleasure seeking (feel-good) mandates
        • Gene expressions are different in type & amplitude for different genotypes
        • Some genotype responses are counter-productive to health
      09/23/09 Confidential Information
    • Obesity Etiology: The Real Causes
      • Altered Gene expression induces increased glucose cravings
      • Compensatory slowing the rate of calorie burning (BMR)
      • Nutrient needs are increasingly stolen from own bio-tissues
        • Muscle degradation for Protein and Mineral needs (reduced energy potential)
        • Bone mineral losses for minerals (can lead to osteopenia, OP, etc.)
      • Compensatory endocrine overexertion, hormone/transmitter resistance (i.e. insulin, thyroid, leptin, dopamine, etc.) and potential glandular exhaustion (with logical consequences)
      • Increased immune (hyper) sensitivities and protective responsiveness (allergies, chronic inflammation, autoimmune)
      • Increased fat storage
      09/23/09 Confidential Information
    • Obesity Etiology: Measuring Weight Loss
      • One Dimensional ‘Linear’ Criteria
          • Bathroom scale; Body Mass Index (BMI); Percent body fat
      • Body Composition Measuring Conflict
        • Fat is lighter than muscle and water
        • Pseudo impression of weight loss due to loss of water retention… NOT fat
        • The Bathroom Scale is not a trusted measuring tool
      • The ‘Chronic’ Dilemma
        • Phase 1 success is almost always followed by Phase 2 failure (and weight re-gain), termed ‘‘Yo-Yo Diet” or Rebound Weight Gain.
      09/23/09 Confidential Information
    • Defining and Understanding Optimal Health and Wellness
        • Elements Involved in Enhancing Optimal Health
          • Increase Energy production
          • Reduce Aberrant Glucose Craving
          • Reduce Food addictive behavior
          • Augment Neuro/endocrine function
          • Increase Stress tolerance and coping skills
          • Improve Immune function
      09/23/09 Confidential Information
    • Body Recomposition Process The ‘Body-Friendly’ Way
      • Nourish ALL the body’s basic needs
      • Address all the important pathways simultaneously
      • Identify Genetic Predispositions (genotypes) for exceptional needs in those pathways ( LifeGen Patented Technology )
      • Adjust ingredient dosage levels to meet the needs of the genotype to ‘normalize’ gene expression and reduce or eliminate aberrant compensatory behaviors; Correcting:
        • Reduced Energy production & regulation
        • Excessive Glucose Cravings
        • Seeking addictive foods
        • Insufficient Neuro/endocrine function
        • Stress intolerance
        • Deficient Immune function
      • THE ONLY Way to Healthy, Successful & Sustainable Body Recomposition
      09/23/09 Confidential Information
    • Unlocking the Neurogenetics of Reward Linked to Optimal Health
      • Reward Deficiency caused by “Dopamine Resistance” is regulated by Dopamine D2 Receptor gene (DRD2) leading to dysfunctional “neurogenobolic” disorder (Central Nervous System induced obesity)
      • DRD2 Gene Polymorphisms cause obesity related bariatric abnormalities.
        • Reduced energy
        • Increase in glucose cravings
        • Increase in percentage body fat
        • Increase in BMI (reduced lean mass)
        • Blunted response to palatable food
        • Overeating
        • Reduced immune competence
      09/23/09 Confidential Information
    • Paradigm Shift Utilizing A multi-pathway “Genetic Positioning Map (GPS)”- Nutrigenomic Principles
      • Utilizing a defined and published Genetic Positioning Map (GPS), LifeGen has developed a paradigm shift in enhancing optimal health and well-being employing a “personalized nutrigenomic” approach.
      • Genotyping prior to treating unveils genomic therapeutic targets (nutrient dosage adjustments) whereby probands can have polymorphisms in at least 1 gene in 1 pathway up to many genes in multiple pathways that influence:
        • Reward seeking/craving behavior
        • energy metabolism
        • neuro/endocrine systems activity
        • stress tolerance
        • immune system programming (recognition & response signaling) to ensure survival
      09/23/09 Confidential Information
    • 09/23/09 Confidential Information
      • KBR509 Irvingia gabonensis
      • (KBR509IG)
      • An indigenous medicinal and culinary plant of central Africa.
      • Family: Irvingiaceae.
      • KBR509IG is a unique extract that comes from a sweet fleshy fruit resembling a mango with a large pit or seed.
      • Traditional culinary and medicinal uses for Irvingia are for thickening soups (seeds) and the treatment of dysentery (leaves).
      • Ig seeds naturally contain high levels of oils, albumins and soluble fiber.
    • Neurophysiological and Genetic Actions of Gabonectin - Introduction
      • Biochemical Mechanisms in-vitro related to enhancing lipid loss.
      • Gene expression experiments
      • PPAR γ gene expression in adipose tissue down regulated in the obese (terminated upon normalization)
        • Not inhibition of effects on TNF-alpha, MMP9 and iNOS from macrophages
      • Leptin down regulation
      • Adiponectin up-regulation
      • Anti-oxidant studies
      • Alpha amylase inhibition experiments
      • Diabetic Blood lipid studies
      • C-Reactive Protein reduced
      • Clinical trials –Double-blind placebo controlled studies showing reduced adipogenesis
      09/23/09 Confidential Information
    • Genetic Mechanisms 09/23/09 Confidential Information
      • PPARγ
      • Gabonectin has been shown to influence PPAR γ expression. PPAR γ is involved in immune cell regulation, lipogenesis, and insulin function, all of which also influence other activities such as energy metabolism.
      • PPAR γ has a significant anti-inflammatory role by inhibiting the production of inflammatory cytokines, and other proteins such as TNF-alpha, MMP9 and iNOS from macrophages.
      • The highest expression of PPAR γ can be found in adipose tissue, colonic epithelia, macrophages, and endothelium, followed by the kidney, liver, and small intestine.
      • PPAR γ is also expressed in skeletal muscles at low levels.
      • Adipose tissue is known to produce and secrete PPARγ, which has roles in the early stage of adipocyte differentiation. Studies have addressed the important role that PPARγ plays in the regulation of insulin sensitivity and glucose homeostasis.
      • The importance of PPAR γ to overall health is punctuated by the fact that a low calorie diet was specifically shown to down-regulate the expression of PPAR γ 2 mRNA in adipose tissue of obese humans, an effect that was subsequently lost during weight maintenance.
      • Other health promoting roles remain intact.
    • Genetic Mechanisms 09/23/09 Confidential Information
      • Leptin
      • Leptin (product of ob gene) can be produced by white and brown adipose tissue, ovaries, skeletal muscle, stomach (lower part of fundic glands), mammary epithelial cells, bone marrow, the pituitary gland and the liver.
      • Leptin is involved in appetite regulation (satiety & cravings), maintaining energy balance, insulin metabolism, and immune modulation via T-cell activation in an atherogenic state, among other roles.
      • Leptin plays an interactive role with dopamine and adiponectin.
      • Polymorphisms in the leptin receptor can alter leptin sensitivity, resistance and function, increasing resource requirements.
    • 09/23/09 Confidential Information Efficacy The Effect of IG on Leptin (ng/dL) 0 4 weeks 8 weeks 10 weeks Placebo 31.39 ± 1.83 29.39 ± 1.39 28.18 ± 1.84 28.45 ± 1.86 IG 32.96 ± 1.63 18.12 ± 1.38 16.84 ± 1.25 16.91 ± 1.36
    • 09/23/09 Confidential Information Efficacy The Effect of IG on Leptin
    • Genetic Mechanisms 09/23/09 Confidential Information
      • Adiponectin
      • The APM1 gene (AdiPose Most abundant gene transcript 1) is an adipose tissue-specific factor that produces adiponectin. Adiponectin expression is regulated by PPARγ transcriptional activity.
      • Adiponectin is specifically expressed in white adipose tissues and is one of the most important adipocytokines, possessing anti-atherogenic, anti-inflammatory and anti-diabetic roles.
      • Adiponectin is involved in glucose regulation, influencing the body's response to insulin and upstream energy regulation.
      • Adiponectin regulates lipid metabolism by catabolizing fatty acids via beta oxidation, an important role in heart & brain health and energy regulation.
      • Adiponectin also has anti-inflammatory effects on endothelial cells lining the walls of blood vessels.
      • As such, high blood levels of adiponectin are associated heart health and a reduced risk of heart attack.
      • IG was shown to stimulate the up-regulation of adiponectin.
    • 09/23/09 Confidential Information Efficacy The Effect of IG on Adiponectin ( µ g/dL) 0 4 weeks 8 weeks 10 weeks Placebo 12.11 ± 3.21 15.18 ± 3.50 14.63 ± 3.47 14.94 ± 3.92 IG 12.16 ± 3.04 24.84 ± 3.81 30.95 ± 3.96 31.59 ± 3.85
    • 09/23/09 Confidential Information Efficacy The Effect of IG on Adiponectin
    • Genetic Mechanisms 09/23/09 Confidential Information Effect of IG on PPARγ in 3T3-L1 adipocytes.
    • Genetic Mechanisms 09/23/09 Confidential Information Effect of IG Extract on Leptin in 3T3-L1 adipocytes
    • Genetic Mechanisms 09/23/09 Confidential Information Effect of IG on Adiponectin in 3T3-L1 adipocytes.
    • Genetic Mechanisms 09/23/09 Confidential Information
      • PPARγ, Leptin and Adiponectin
      • IG down-regulated expression of PPARγ and leptin, and then the up-regulated expression of adiponectin.
      • Gabonectin™, among other health promoting roles, can play an important role in immune health, energy homeostasis and in the control and/or management of healthy body composition.
    • Antioxidant
      • Antioxidant Studies
      • In 2003 researchers at the University of Yaounde showed that Ig extracts have antioxidant effects and radical scavenging activities that can protect against atherosclerotic plaques and help prevent against CV diseases.
      09/23/09 Confidential Information
    • 09/23/09 Confidential Information Efficacy The Effect of IG on C-Reactive Protein (mg/dL) 0 4 weeks 8 weeks 10 weeks Placebo 14.62 ± 4.50 14.55 ± 4.11 14.45 ± 3.20 14.45 ± 3.96 IG 14.90 ± 4.12 9.11 ± 4.92 7.12 ± 4.44 7.15 ± 4.49
    • 09/23/09 Confidential Information Efficacy The Effect of IG on C-Reactive Protein
    • Efficacy
      • Diabetes and Blood Lipid Studies
      • In 1990 researchers at the University of Benin studied the effects of Irvingia gabonensis (dikanut) in the diet of eleven Type II diabetics. Levels of plasma lipids, glucose and erythrocyte ATPases were monitored for one month. The dikanut supplement lowered blood lipids. The reduction in plasma lipids was primarily due to a decrease in LDL + VLDL-cholesterol and triglycerides levels. HDL-cholesterol was increased. When dikanut was consumed by the diabetics for four weeks significant reduction of plasma glucose levels were also observed. West Afr J Med. 1990 Apr-Jun;9(2):108-15.
      09/23/09 Confidential Information
    • Efficacy
      • In 1993 a feeding trial involving a crude Irvingia extract and diabetic rats was maintained for 4 weeks. The levels of digestive and membrane-bound enzymes of the intestine, and hepatic glycolytic enzymes were determined. The effect of the supplements on intestinal morphology was also assessed.
      • A general reduction in the levels of all the intestinal enzymes assayed was observed. Evidence was obtained for a marked alteration in the intestinal morphology.
      • It was concluded that the reduced absorption of glucose resulted in its lowered level in the blood and urine. The disruption of the mucosal membrane may also curtail the absorption of glucose. On the other hand, the activities of hepatic glycolytic enzymes became elevated to efficiently utilize the low substrates reaching the liver. The dietary fibers caused a shift away from the depletion of glycogen by the diabetic rat to synthesis of the storage polysaccharide. Ann Nutr Metab. 1993;37(1):14-23
      09/23/09 Confidential Information
    • Efficacy
      • Diabetes and Blood Lipid Studies
      • In 2006 researchers at the University of Yaounde examined the hypoglycemic effect of IG seeds in streptozotocin-diabetic rats. A single oral administration of the methanol extract at doses of 150 and 250mg/kg significantly (P < 0.001) lowered the plasma glucose levels in diabetic rats two hours after treatment. Afr. J. Trad. CAM (2006) 3(4):74-77.
      09/23/09 Confidential Information
    • Efficacy
      • In 2006 researchers at the University of Yaounde evaluated the action of IG seed fractions in reducing or slowing down the intestinal absorption of glucose in normoglycemic rats.
      • The crude seeds (CS), the defatted seeds (DS) and the protein fraction (PF) were administered at dose of 400mg/kg body weight to normoglycemic rats submitted to oral glucose test (OGTT) with glucose (2g/kg body weight).
      • The results obtained show a significant reduction of the postprandial glucose level after a glucose load of (2g/kg body weight) as well as fasting blood glucose levels with the three fractions. Afr J Trad CAM (2006) 3(4):94-101.
      09/23/09 Confidential Information
    • Efficacy
      • Weight loss Study 1
      • In 2005 researchers at the University of Yaounde showed that 3 weeks of oral treatment with the IG aqueous extract on normolipidemic guinea pigs on a high fat diet (HFD), at a dose of 250 mg/kg induced a significant decrease in weight and a significant increase in HDL cholesterol. This was accompanied by a significant decrease in plasma triglycerides and LDL cholesterol. Publication in progress
      09/23/09 Confidential Information
    • Efficacy
      • Weight loss study 2
      • In 2005 researchers at the University of Yaounde carried out a double blind randomised study involving 40 subjects (mean age 42.4 years). Twenty-eight subjects received IG (1.05 g three time a day for one month) while 12 were on placebo (P) and the same schedule. During the one-month study period all subjects were on a normocaloric diet and evaluated every week by a dietetic record book.
      • At the end, the mean body weight of the IG group was decreased by 5.26  2.37% (p<0.0001) and that of the placebo group by 1.32  0.41% (p<0.02). The difference observed between the IG and the placebo groups was significant (p < 0.01). The obese patients taking the IG treatment also had a significant decrease of total cholesterol, LDL- cholesterol, triglycerides, and an increase of HDL-cholesterol. Lipids in Health and Disease 2005, 4:12
      09/23/09 Confidential Information
    • Efficacy 09/23/09 Confidential Information 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0% 3.5% 4.0% % Change 2 Weeks 4 Weeks Weight Loss IG Placebo -1.0% -0.5% 0.0% 0.5% 1.0% 1.5% 2.0% % Change 2 Weeks 4 Weeks Fat Loss IG Placebo -1.0% 0.0% 1.0% 2.0% 3.0% 4.0% 5.0% 6.0% % Change 2 Weeks 4 Weeks Waist Reduction IG Placebo 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0% 3.5% 4.0% % Change 2 Weeks 4 Weeks Hip Reduction IG Placebo
    • 09/23/09 Confidential Information Efficacy The use of a Irvingia g. in weight management in human volunteers Julius Oben, Claudia Momo-Nguefack and Judith Ngondi Laboratory of Nutrition and Nutritional Biochemistry, Faculty of Science, BP 8418, University of Yaounde, Yaounde, Cameroon.
    • RATIONALE
      • Popular weight loss tactics have been unsuccessful.
      • In addition to recommending healthy lifestyle activities and calorie reduction, popular weight loss products generally target a single mechanistic path (Ex: fat blocking, appetite suppression, cortisol inhibition, CNS stimulation, etc.) to exert weight loss effects in combination with some form of caloric/nutrient deprivation.
      • Such tactics do not make the body happy and ultimately trigger a ‘protective’ energy conserving lowering of the BMR, an increase in fat storage and increased cravings (i.e. for carbs). These automatic protective responses almost always cause the “weight gain rebound effect” and usually result in gaining more weight than was originally lost from using unhealthy tactics (aka Yo-Yo diet).
      • Research demonstrates the healthy effects of IG on weight, body composition factors, various blood lipid fractions, antioxidant effects, inflammation, blood glucose, cardiovascular health factors and gene expression in overweight and obese humans.
      09/23/09 Confidential Information
    • Protocol
      • A recent study was a randomized, double-blind, placebo-controlled design, involving 102 obese or overweight participants (ages 19-50, BMI>26kg/m2) for 10 weeks.
      • The participants were randomly divided into two groups
        • Placebo Group
        • IG Group - 150 mg twice daily before meals
      • Weight, blood lipids, fasting blood glucose, serum leptin, c-reactive protein and adiponectin was taken at baseline, and at 4, 8 and 10 weeks.
      • No major dietary changes or exercises were suggested during the study.
      09/23/09 Confidential Information
    • 09/23/09 Confidential Information Efficacy The effect of IG on Weight (kg) 0 4 weeks 8 weeks 10 weeks Placebo 96.4 ±12.3 95.8 ±8.2 96.1 ±10.6 95.7 ±15.2 IG 97.9 ± 9.1 94.3 ± 5.5 89.7 ± 4.7 85.1 ± 3.1
    • 09/23/09 Confidential Information Efficacy The Effect of IG on Weight (kg)
    • 09/23/09 Confidential Information Efficacy The Effect of IG on Fasting Blood Glucose (mg/dL) 0 4 weeks 8 weeks 10 weeks Placebo 79.42 ±11.61 78.34 ± 10.41 76.53 ± 10.42 77.32 ± 8.90 IG 85.55 ± 5.59 66.64 ± 10.29 62.74 ± 9.25 59.30 ± 4.93
    • 09/23/09 Confidential Information Efficacy The Effect of IG on Fasting Blood Glucose (% Change)
    • 09/23/09 Confidential Information Efficacy The Effect of IG on Total Cholesterol (mg/dL) 0 4 weeks 8 weeks 10 weeks Placebo 146.20 ± 38.14 140.40 ± 11.10 150.06 ± 13.20 149.47 ± 19.16 IG 151.74 ± 18.52 133.74 ± 16.63 120.18 ± 11.97 111.92 ± 5.83
    • 09/23/09 Confidential Information Efficacy The Effect of IG on Total Cholesterol (% Change)
    • 09/23/09 Confidential Information Efficacy The Effect of IG on LDL Cholesterol (mg/dL) 0 4 weeks 8 weeks 10 weeks Placebo 76.13 ± 8.02 79.40 ± 7.51 74.36 ± 9.02 73.87 ± 8.45 IG 82.21 ± 8.06 71.81 ± 5.92 64.73 ± 8.91 59.77 ± 4.98
    • 09/23/09 Confidential Information Efficacy The Effect of IG on LDL Cholesterol (% Change)
    • Molecular Mechanisms 09/23/09 Confidential Information α -Amylase Inhibition
    • 09/23/09 Confidential Information
      • Study Summary
      • Over the 10 week study period, compared to the placebo group, the IG group:
        • lost significantly (p≤0.01) more weight (18 times more)
        • had significantly (p≤0.01) improved body composition
        • achieved healthier outcomes as measured by important health parameters
        • had a significantly (p≤0.01) higher reduction in the waist to hip ratio
      • IG is an effective and ‘body friendly’ agent to aid in healthy body recomposition by addressing multiple pathways and mechanisms that improve overall heath
      Efficacy
    • Conclusion
      • IG works via multiple pathways to promote efficient metabolism and optimal health; a prerequisite to healthy, effective, and sustainable body re-composition (incl. fat loss) by such mechanisms as:
        • Reducing immune mediated inflammatory-molecule (CRP), its binding to leptin, reducing leptin resistance and lowering serum leptin levels
        • Increasing adinopectin levels, increasing lipid oxidation; also anti-atherogenic, anti-inflammatory and anti-diabetic effects
        • Reducing PPAR γ expression, an adipogenic gene involved in immune cell regulation, lipogenesis, and insulin function; implicated in insulin resistance and the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer
        • Inhibiting α-amylase activity, reducing the absorption of sugar
        • Reducing glucose levels and insulin induced lipogenesis
        • Reducing adipocyte triglycerides and glucose-3-phophate dehydrogenase (reducing the conversion of glycerol to triglycerides)
      09/23/09 Confidential Information
    • Conclusion
      • The primary benefits improve energy management, healthy neuro-endocrine function, immune support, and gene expression thereby reducing fat in a healthy consistent and ‘body friendly’ manner; as opposed to deprivation tactics that traumatize health.
      • KBR509IG is far better than any of the ‘works-one-way’ products in the market.
      09/23/09 Confidential Information
    • 09/23/09 Confidential Information
      • KBR509IG Nutrigenomic Dosage:
        • 300 to 500 mg per day divided in two equal (pre-meal) doses.
      Intake Level
    • Commercialization Issues 09/23/09 Confidential Information
      • KBR509 Irvingia gabonensis: GABONECTIN
      • Research was conducted on an IG extract, which was found to possess hypolipidemic, anti  -amylase, anti-inflammatory, and various types of gene expression activity.
      • Dr. Julius Oben obtained patents on the Metabolic Syndrome X benefits of IG and marketed those aspects through Gateway Health Alliances, Inc. (GHA) for the IGOB131.
      • Gateway collaborated with LifeGen, Inc. scientists (BD & KB) to explore and expand upon the understanding of IGs various mechanisms.
      • Gabonectin™, a KBR509IG extract (patent pending), is being offered by LifeGen, Inc. to enhance neurogenobolic efficiency and competence, especially for genotypes possessing polymorphisms in the PPAR γ , leptin, and adiponectin, FTO and DRD2 genes.
        • Important to overall health and wellness, and for c orrecting body composition maladies
        • LifeGen has submitted a patent application for these benefits
    • Commercialization Issues
      • Gateway entered into an exclusive license with Life Extension (LE) to market IG.
      • IG is the most successful weight loss product for LE and has become one of the top selling SKU’s of all Life Extension Products
      • Life Extension is being confronted with IG supply issues
      • LifeGen has entered into an exclusive Sales & Supply Agreement with the company that bought up all existing IG source from a major region in Africa.
      • LifeGen is putatively offering their GABONECTIN to AMWAY
      09/23/09 Confidential Information
    • LifeGen, Inc. 09/23/09 Confidential Information
    • Patented Genomic Solution – Novel Exclusive Optimal Health Nutraceutical
      • OPTIMAL HEALTH & WELL-BEING TARGETS
      • Pathways
      • Energy
      • Pleasure
      • Neuro-endocrine
      • Immune competence
      • Stress
      • Mech Of Action
      • Anti-oxidation
      • Anti-inflammatory
      • α –Amylase starch blockade
      • Anti-Adipogenesis
      • Gene Expression
      • Gene Expressions
      • PPAR
      • LEPTIN
      • ADIPONECTIN
      • FTO
      • DRD2
      • Optimal Health Genomic Solution
      • Gabonectin™
      • Synaptamine ™
        • Brain reward control
      • Chia (TriChia™)
        • Whole Food Source of Protein (complete) EFAs, and Fiber
      09/23/09 Confidential Information
      • “ Any one part of your body cannot be well, unless you care for the whole body” (attributed to Plato)
        • The body is a complex ‘symphony’ of inter-related, interactive, and interdependent systems all working together to achieve optimal health and life.
        • LifeGen® Provides
        • “ Gene-Guided Precision Nutrition”
        • Solutions
      09/23/09 Confidential Information